The American Society of Hematology (ASH) Annual Meeting and Exposition is the last big clinical conference of the year. As we head into 2024, which areas are set to attract investment with their latest datasets, and which are in danger of falling flat? ASH will see the latest data reveals on CAR-T products, multiple myeloma, leukaemia and…
The pharma world is on tenterhooks, waiting to see how the Inflation Reduction Act will impact drug innovation and pricing, and how the Federal Trade Commission could foil M&A plans. As valid as these concerns are, however, they shouldn't overshadow what is arguably a more pressing issue: the shifting dynamics in the US payer landscape. The…
As part of Evaluate’s partnership with Galen Growth, we are delighted to bring you this report on the emergence of artificial intelligence (AI) and the use of Generative…
The pharmaceutical sector is entering new and unfamiliar territory. Key assumptions, such as the unrivalled profitability of the US market and the reliance on large…
After a promising start to the year on the M&A front, things have slowed down significantly in the third quarter. While it was generally agreed that mega-mergers were…
After a promising start to the year on the M&A front, things have slowed down significantly in the third quarter. While it was generally agreed that mega-mergers were…
After a hopeful start in M&A for the year, did Q3 keep up the pace or change gears? Venture financing has seen a shift, and the IPO window appears to be nudging open.…
As part of Evaluate’s partnership with Galen Growth, we are delighted to bring you this report on the importance of clinical evidence within the digital healthcare…
After a hopeful start in M&A for the year, did Q3 keep up the pace or change gears? Venture financing has seen a shift, and the IPO window appears to be nudging open.…
As part of Evaluate’s partnership with Galen Growth, we are delighted to bring you this report on the importance of clinical evidence within the digital healthcare…
